{
    "clinical_study": {
        "@rank": "102466", 
        "arm_group": [
            {
                "arm_group_label": "Dabigatran"
            }, 
            {
                "arm_group_label": "Warfarin or other NOACs"
            }
        ], 
        "brief_summary": {
            "textblock": "This study plans to describe utilization patterns for oral anticoagulants over time in\n      patients with non-valvular atrial fibrillation at risk for stroke  using electronic claims\n      data from a United States commercial insurance database."
        }, 
        "brief_title": "Anticoagulant Utilization Pattern", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  A recorded diagnosis of atrial fibrillation\n\n          -  Initiation of oral anticoagulant medication\n\n          -  CHA2DS2-VASc-Score >=1\n\n          -  At least 18 years of age on the date of anticoagulant initiation\n\n        Exclusion criteria:\n\n          -  Patients with missing or ambiguous age or sex information\n\n          -  Patients with documented evidence of valvular disease\n\n          -  Patients with less than 12 months enrolment in the UnitedHealth Research Database\n             preceding the first dispensing\n\n          -  Patients with prior use of any oral anticoagulant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients 18 years of age and older with non-valvular AF at risk for stroke treated with\n        oral anticoagulation"
            }
        }, 
        "enrollment": {
            "#text": "100000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847560", 
            "org_study_id": "1160.177"
        }, 
        "intervention_browse": {
            "mesh_term": "Anticoagulants"
        }, 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "1160.177.01001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Description of Warfarin and NOAC Utilization Patterns Including Initiation, Switching, and Discontinuation", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of patients dispensed specific anticoagulants and anticoagulant doses (for new oral anticoagulant medications)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 years"
            }, 
            {
                "measure": "Description of the characteristics of patients with non-valvular atrial fibrillation initiating oral anticoagulants", 
                "safety_issue": "No", 
                "time_frame": "up to 6 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}